Clinical Trials Logo

Leukemia clinical trials

View clinical trials related to Leukemia.

Filter by:

NCT ID: NCT00131313 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Start date: January 2003
Phase: Phase 4
Study type: Interventional

This research study measures the safety and efficacy of the combination of three drugs that are approved, Nipent, Rituxan and Cytoxan in the treatment of Chronic Lymphocytic Leukemia (CLL). These drugs are being given together for investigational purposes as the specific combination of these three drugs has not been approved for treatment of CLL by the FDA.

NCT ID: NCT00131053 Recruiting - Clinical trials for Lymphoblastic Leukemia, Acute

Applying Pediatric Regimens to Younger Adult Patients With Acute Lymphoblastic Leukemia (ALL)

Start date: September 2002
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate the efficacy and safety for treating adult ALL patients with the pediatric protocol.

NCT ID: NCT00131027 Recruiting - Clinical trials for Lymphoblastic Leukemia, Acute

High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL)

Start date: September 2002
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the clinical efficacy of high-dose methotrexate consolidation therapy for adult patients with BCR-ABL-negative ALL.

NCT ID: NCT00130702 Completed - Clinical trials for Myelogenous Leukemia, Acute

Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia

Start date: August 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine how effective, and to what extent, Iressa is in the treatment of acute myelogenous leukemia.

NCT ID: NCT00130195 Completed - Clinical trials for Acute Lymphoblastic Leukemia

Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL)

Start date: September 2002
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the clinical efficacy and safety of imatinib-combined chemotherapy on newly diagnosed BCR-ABL-positive ALL.

NCT ID: NCT00129948 Terminated - Clinical trials for Leukemia, Myeloid, Acute

Study for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Start date: July 2005
Phase: Phase 2
Study type: Interventional

This is a phase 2, single-arm, open-label, multi-center study to establish the safety and efficacy of Troxatylâ„¢ (troxacitabine) administered as a continuous infusion for 5 days to subjects with AML.

NCT ID: NCT00129740 Completed - Clinical trials for Leukemia, Myelogenous, Chronic

Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)

Start date: June 27, 2005
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if an experimental agent, AMN107 (nilotinib), can help to control CML in chronic phase. The safety of this experimental agent will also be studied.

NCT ID: NCT00129558 Withdrawn - Leukemia Clinical Trials

A Study to Evaluate PT-523 in Patients With Refractory Leukemia

Start date: July 2005
Phase: Phase 1/Phase 2
Study type: Interventional

This Phase I/II, multi-centered, non-randomized, trial is designed to determine a safe dose of PT-523 for subjects, and to make preliminary evaluations on the activity of PT-523 as therapy in subjects with refractory leukemia.

NCT ID: NCT00129168 Completed - Leukemia, Myeloid Clinical Trials

Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia (AML)

Start date: August 2005
Phase: Phase 1/Phase 2
Study type: Interventional

Chemotherapy drugs use different ways to stop cancer cells from dividing so they stop growing or die. Zosuquidar may help daunorubicin and cytarabine kill more cancer cells by making cancer cells more sensitive to the drugs. It is not yet known whether daunorubicin and cytarabine are more effective with or without zosuquidar in treating acute myeloid leukemia.

NCT ID: NCT00126893 Terminated - Myeloid Leukemia Clinical Trials

Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia

Start date: October 2005
Phase: Phase 1
Study type: Interventional

This is a single center Phase 1 study to evaluate the safety, pharmacokinetics and pharmacodynamics of CC-401 in subjects with refractory acute myelogenous leukemia.